newsfilter
← Latest News
GlobeNewswire·

Pardes Biosciences to Present at the International Conference On Antiviral Research 2022

CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment a